Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 12/20 | 0.55 |
| ▸ | NPC1 | O15118 | 10/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28402085 | 0.96 | MEN1 (0.64) | MEN1KMT2ARAB9ANPC1NOTUM | |
| SCHEMBL2319256 | 0.83 | LMNA (0.52) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15299348 | 0.83 | MEN1 (0.47) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23364835 | 0.82 | MEN1 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2320359 | 0.82 | MEN1 (0.47) | MEN1KMT2ANOTUMSMN1; SMN2NFKB1 | |
| SCHEMBL31124848 | 0.82 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1NOTUM | |
| SCHEMBL28977122 | 0.81 | RAB9A (0.51) | MEN1KMT2ARAB9ANPC1CASP3 | |
| SCHEMBL2321001 | 0.81 | RAB9A (0.51) | MEN1KMT2ARAB9ANPC1NOTUM | |
| SCHEMBL24168675 | 0.81 | MEN1 (0.46) | MEN1KMT2ARAB9ANPC1NOTUM | |
| SCHEMBL28413035 | 0.81 | SMN1; SMN2 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292549-B | Oxadiazoline containing trifluoromethyl isoxazole ring and preparation method thereof | 上海大学 | 2023-06-09 | — | — | CN | claimed |
| CN-113292549-A | Oxadiazoline containing trifluoromethyl isoxazole ring and preparation method thereof | 上海大学 | 2021-08-24 | — | — | CN | claimed |
| CN-113292549-B | Oxadiazoline containing trifluoromethyl isoxazole ring and preparation method thereof | 上海大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-111087355-B | Synthetic method of 5-trifluoromethyl-isoxazole compound | 福州大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-113292549-A | Oxadiazoline containing trifluoromethyl isoxazole ring and preparation method thereof | 上海大学 | 2021-08-24 | — | — | CN | disclosed |
| CN-111087355-A | Synthetic method of 5-trifluoromethyl-isoxazole compound | 福州大学 | 2020-05-01 | — | — | CN | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-8518974-B2 | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518974-B2 | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-07-19 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | MEN1 4423/4885KMT2A 3647/4885RAB9A 1044/4885 |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | MEN1 4496/4885KMT2A 3542/4885RAB9A 1058/4885 |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | MEN1 4496/4885KMT2A 3542/4885RAB9A 1058/4885 |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | MEN1 4496/4885KMT2A 3542/4885RAB9A 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.